Go Pro
→ ALERT: Drop these 5 stocks before the market opens tomorrow! (From Weiss Ratings) (Ad)tc pixel Free IDYA Stock Alerts

IDEAYA Biosciences (IDYA) Financials

IDEAYA Biosciences logo
$38.41 -0.20 (-0.52%)
Closing price 09/18/2026 04:00 PM Eastern
Extended Trading
$37.86 -0.55 (-1.43%)
As of 09/18/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for IDEAYA Biosciences

Annual Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -34 -42 -35 -50 -59 -113 -274 -114
Consolidated Net Income / (Loss)		 -34 -42 -34 -50 -59 -113 -274 -114
Net Income / (Loss) Continuing Operations		 -34 -42 -34 -50 -59 -113 -274 -114
Total Pre-Tax Income 		-36 -44 -35 -50 -63 -113 -274 -114
Total Operating Income		 -36 -44 -35 -50 -63 -134 -327 -159
Total Gross Profit		 0.00 0.00 20 28 51 23 7.00 219
Total Revenue		 0.00 0.00 20 28 51 23 7.00 219
Operating Revenue		 0.00 0.00 20 28 51 23 7.00 219
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 36 44 55 78 113 158 334 378
Selling, General & Admin Expense		 4.67 9.95 15 20 24 28 39 63
Research & Development Expense		 32 34 40 58 90 130 295 315
Total Other Income / (Expense), net		 0.00 0.00 0.00 0.51 0.00 21 52 46
Other Income / (Expense), net		 - - - 0.51 - 21 52 46
Basic Earnings per Share		 ($35.92) ($3.36) ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Weighted Average Basic Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 41.44M 57.52M 81.68M 88.49M
Diluted Earnings per Share		 ($35.92) ($3.36) ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Weighted Average Diluted Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 41.44M 57.52M 81.68M 88.49M
Weighted Average Basic & Diluted Shares Outstanding		 956.25K 12.50M 24.72M 35.25M 48.39M 74.56M 87.54M 87.81M

Quarterly Income Statements for IDEAYA Biosciences

This table shows IDEAYA Biosciences' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -35 -40 -53 -52 -135 -72 -77 119 -83 -99 -112
Consolidated Net Income / (Loss)		 -34 -40 -53 -52 -130 -72 -77 119 -83 -99 -112
Net Income / (Loss) Continuing Operations		 -34 -40 -53 -52 -130 -72 -77 119 -83 -99 -112
Total Pre-Tax Income 		-45 -51 -65 -67 -156 -72 -89 108 -61 -99 -122
Total Operating Income		 -42 -51 -65 -67 -144 -84 -89 108 -95 -109 -122
Total Gross Profit		 3.92 0.00 0.00 0.00 7.00 0.00 0.00 208 11 6.56 8.86
Total Revenue		 3.92 0.00 0.00 0.00 7.00 0.00 0.00 208 11 6.56 8.86
Operating Revenue		 3.92 0.00 0.00 0.00 7.00 0.00 0.00 208 11 6.56 8.86
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 46 51 65 67 151 84 89 99 105 115 131
Selling, General & Admin Expense		 7.07 8.21 10 9.74 11 14 15 16 19 19 22
Research & Development Expense		 39 43 55 57 140 71 74 83 87 96 109
Total Other Income / (Expense), net		 -2.64 0.00 0.00 0.00 -11 12 0.00 0.00 33 10 0.00
Other Gains / (Losses), net		 - 11 12 15 - - 11 11 - - 9.84
Basic Earnings per Share		 ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.35 ($0.93) ($1.11) ($1.22)
Weighted Average Basic Shares Outstanding		 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 88.53M 88.49M 88.70M 92.06M
Diluted Earnings per Share		 ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.33 ($0.91) ($1.11) ($1.22)
Weighted Average Diluted Shares Outstanding		 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 89.69M 88.49M 88.70M 92.06M
Weighted Average Basic & Diluted Shares Outstanding		 74.56M 75.69M 84.48M 86.43M 87.54M 87.58M 87.64M 87.67M 87.81M 87.86M 96.49M

Annual Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 15 14 38 20 -23 89 -73 29
Net Cash From Operating Activities		 -28 -39 55 -56 -87 -115 -248 -71
Net Cash From Continuing Operating Activities		 -28 -39 55 -56 -87 -115 -248 -71
Net Income / (Loss) Continuing Operations		 -34 -42 -34 -50 -59 -113 -274 -114
Consolidated Net Income / (Loss)		 -34 -42 -34 -50 -59 -113 -274 -114
Depreciation Expense		 0.89 1.25 1.38 1.73 2.10 2.48 2.39 2.70
Amortization Expense		 -0.81 -0.47 0.58 3.14 0.72 -10 -22 -8.08
Non-Cash Adjustments To Reconcile Net Income		 4.99 3.27 3.59 -15 -35 18 35 46
Changes in Operating Assets and Liabilities, net		 1.65 -1.38 84 4.42 3.51 -13 12 1.87
Net Cash From Investing Activities		 -63 2.27 -146 -70 -33 -158 -503 70
Net Cash From Continuing Investing Activities		 -63 2.27 -146 -70 -33 -158 -503 70
Purchase of Property, Plant & Equipment		 -1.71 -1.35 -0.49 -2.64 -3.44 -2.37 -3.86 -2.37
Purchase of Investments		 -133 -88 -242 -315 -256 -596 -1,191 -608
Sale and/or Maturity of Investments		 72 92 97 248 226 440 693 680
Net Cash From Financing Activities		 105 51 129 145 97 363 678 30
Net Cash From Continuing Financing Activities		 105 51 129 145 97 363 678 30
Issuance of Common Equity		 0.00 50 128 144 96 353 665 26
Other Financing Activities, net		 0.09 0.29 1.19 1.50 1.45 9.56 12 3.43
Cash Interest Paid		 0.10 0.09 0.08 0.07 0.06 0.07 0.03 0.00
Cash Income Taxes Paid		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Cash Flow Statements for IDEAYA Biosciences

This table details how cash moves in and out of IDEAYA Biosciences' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 5.20 -49 75 217 -316 46 -15 184 -186 45 115
Net Cash From Operating Activities		 -24 -44 -33 -49 -122 -60 -62 142 -90 -75 -88
Net Cash From Continuing Operating Activities		 -24 -44 -33 -49 -122 -60 -62 142 -90 -75 -88
Net Income / (Loss) Continuing Operations		 -34 -40 -53 -52 -130 -72 -77 119 -83 -99 -112
Consolidated Net Income / (Loss)		 -34 -40 -53 -52 -130 -72 -77 119 -83 -99 -112
Depreciation Expense		 0.63 0.62 0.62 0.58 0.57 0.60 0.72 0.66 0.72 0.69 0.69
Amortization Expense		 -3.48 -5.85 -6.17 -4.93 -4.85 -3.25 -2.18 -1.61 -1.05 -0.76 -0.59
Non-Cash Adjustments To Reconcile Net Income		 -8.96 6.31 9.73 9.22 9.49 10 12 12 12 15 7.21
Changes in Operating Assets and Liabilities, net		 22 -5.32 16 -2.28 3.45 4.24 4.61 12 -19 8.90 17
Net Cash From Investing Activities		 -112 -354 69 -20 -197 80 46 42 -98 119 -156
Net Cash From Continuing Investing Activities		 -112 -354 69 -20 -197 80 46 42 -98 119 -156
Purchase of Property, Plant & Equipment		 -0.84 -1.33 -0.97 -0.46 -1.10 -1.33 -0.66 -0.04 -0.33 -0.97 -0.87
Purchase of Investments		 -222 -476 -165 -214 -337 -105 -128 -139 -236 -43 -313
Sale and/or Maturity of Investments		 111 123 234 194 141 186 174 181 139 163 158
Net Cash From Financing Activities		 141 349 39 287 2.75 26 1.21 0.30 2.13 1.18 359
Net Cash From Continuing Financing Activities		 141 349 39 287 2.75 26 1.21 0.30 2.13 1.19 359
Issuance of Common Equity		 135 344 37 284 0.25 25 0.80 -0.08 0.63 0.00 358
Other Financing Activities, net		 5.85 5.46 2.08 2.44 2.50 1.13 0.41 0.38 1.50 1.19 0.85

Annual Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 97 113 298 381 388 649 1,124 1,109
Total Current Assets		 91 102 289 251 370 533 690 667
Cash & Equivalents		 21 34 72 92 69 157 84 113
Short-Term Investments		 69 65 212 155 296 368 592 527
Accounts Receivable		 - 0.00 1.88 1.10 0.21 0.02 0.00 0.00
Prepaid Expenses		 0.71 2.70 3.14 3.12 5.41 7.50 13 21
Other Current Assets		 - - - - - - 0.00 5.97
Plant, Property, & Equipment, net		 5.15 4.64 4.27 4.76 6.51 6.16 8.97 8.22
Total Noncurrent Assets		 0.72 6.71 5.39 126 11 111 425 434
Long-Term Investments		 - 1.53 0.00 121 8.32 107 406 410
Other Noncurrent Operating Assets		 0.72 5.18 5.39 4.30 2.69 3.03 20 24
Total Liabilities & Shareholders' Equity		 97 113 298 381 388 649 1,124 1,109
Total Liabilities		 7.10 13 100 80 39 28 65 86
Total Current Liabilities		 5.41 6.94 39 45 32 27 46 59
Accounts Payable		 1.42 0.71 0.95 2.10 4.28 6.60 15 18
Accrued Expenses		 3.58 5.02 8.52 12 17 19 30 41
Current Deferred Revenue		 0.30 0.00 28 29 8.57 0.00 0.00 0.00
Other Current Liabilities		 0.11 1.21 1.56 1.70 1.87 1.75 0.30 0.34
Total Noncurrent Liabilities		 1.69 5.66 61 35 6.80 1.13 19 28
Noncurrent Deferred Revenue		 1.57 0.00 56 31 5.19 0.00 0.00 0.00
Other Noncurrent Operating Liabilities		 0.11 5.66 5.20 3.48 1.61 1.13 19 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -49 100 198 302 349 621 1,059 1,023
Total Preferred & Common Equity		 -49 100 198 302 349 621 1,059 1,023
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 -49 100 198 302 349 621 1,059 1,023
Common Stock		 1.60 193 325 479 588 969 1,681 1,757
Retained Earnings		 -51 -92 -127 -177 -235 -348 -623 -737
Accumulated Other Comprehensive Income / (Loss)		 -0.03 0.07 0.01 -0.71 -2.87 0.56 0.81 2.27

Quarterly Balance Sheets for IDEAYA Biosciences

This table presents IDEAYA Biosciences' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 365 528 533 962 974 1,240 1,101 1,041 1,185 1,030 1,310
Total Current Assets		 344 502 482 709 713 932 708 686 803 696 864
Cash & Equivalents		 67 103 152 108 183 400 130 115 299 158 273
Short-Term Investments		 272 391 317 590 519 520 563 555 488 514 556
Accounts Receivable		 0.47 0.16 6.70 0.02 0.00 0.02 0.00 0.00 0.00 0.00 0.00
Prepaid Expenses		 4.02 7.91 6.73 11 12 12 15 16 16 18 20
Other Current Assets		 - - - - - - - - - 6.56 15
Plant, Property, & Equipment, net		 6.72 6.83 6.19 6.91 7.12 8.24 8.87 8.82 8.17 8.63 8.28
Total Noncurrent Assets		 14 19 45 245 253 299 384 347 374 326 437
Long-Term Investments		 12 16 42 243 251 280 359 322 350 302 414
Other Noncurrent Operating Assets		 2.33 2.56 2.17 2.63 2.29 19 25 25 24 24 23
Total Liabilities & Shareholders' Equity		 365 528 533 962 974 1,240 1,101 1,041 1,185 1,030 1,310
Total Liabilities		 31 26 25 26 42 59 77 82 93 93 111
Total Current Liabilities		 30 25 25 25 41 41 51 55 65 65 83
Accounts Payable		 4.38 5.87 5.17 6.29 16 13 18 17 18 21 31
Accrued Expenses		 17 15 16 18 24 28 33 38 45 44 51
Current Deferred Revenue		 6.26 2.82 1.44 0.00 - - - - 0.49 0.00 0.00
Other Current Liabilities		 1.92 1.96 2.10 1.15 0.61 0.00 0.31 0.32 0.33 0.35 1.19
Total Noncurrent Liabilities		 1.12 0.61 0.00 1.26 1.26 19 26 26 29 28 28
Noncurrent Deferred Revenue		 0.00 0.00 0.00 0.00 - - - - 1.68 0.00 0.00
Other Noncurrent Operating Liabilities		 1.12 0.61 0.00 1.26 1.26 19 26 26 27 28 28
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 334 502 508 935 932 1,180 1,024 960 1,092 937 1,199
Total Preferred & Common Equity		 334 502 508 935 932 1,180 1,024 960 1,092 937 1,199
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 334 502 508 935 932 1,180 1,024 960 1,092 937 1,199
Common Stock		 594 790 823 1,324 1,374 1,669 1,718 1,731 1,743 1,773 2,148
Retained Earnings		 -259 -287 -314 -388 -441 -493 -695 -773 -653 -835 -948
Accumulated Other Comprehensive Income / (Loss)		 -1.41 -1.18 -0.75 -0.92 -1.42 3.84 1.59 1.52 2.05 -0.49 -1.67

Annual Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 43.01% 82.28% -54.08% -70.07% 3,024.43%
EBITDA Growth		 0.00% -19.70% 23.25% -34.48% -32.93% -137.88% -143.97% 59.48%
EBIT Growth		 0.00% -21.57% 20.16% -40.79% -25.60% -115.08% -143.23% 58.58%
NOPAT Growth		 0.00% -21.57% 20.16% -42.23% -24.34% -115.08% -143.23% 51.28%
Net Income Growth		 0.00% -22.21% 17.82% -44.26% -17.87% -92.59% -142.98% 58.58%
EPS Growth		 0.00% 90.65% 58.33% -0.71% -0.71% -38.03% -71.43% 61.90%
Operating Cash Flow Growth		 0.00% -42.34% 241.08% -200.57% -56.29% -32.18% -114.87% 71.28%
Free Cash Flow Firm Growth		 0.00% 0.00% 292.48% -189.19% -60.54% -22.71% -104.56% 50.43%
Invested Capital Growth		 0.00% 84.17% -103,937.80% 21.99% 64.40% 51.39% -99.76% -16.29%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% -21.40% 2.13% -0.42% 78.43% 1.80%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% -36.93% -19.01% -14.63% -42.70% 45.43%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% -33.84% -14.83% -13.01% -45.48% 45.57%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% -35.21% -14.83% -13.01% -45.48% 23.73%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% -35.65% -11.37% -9.45% -54.10% 29.26%
EPS Q/Q Growth		 0.00% 0.00% 0.00% -45.36% -2.90% 1.01% -44.83% 33.33%
Operating Cash Flow Q/Q Growth		 0.00% -3.23% -4.95% -9.98% -8.34% -0.33% -65.41% 30.47%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -6.83% -0.89% -54.53% 11.03%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 2.33% 5.86% -271.96% -16.54% 40.31%
Profitability Metrics		 - - - - - - - -
Gross Margin		 0.00% 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 0.00% 0.00% -170.87% -160.68% -117.18% -607.12% -4,948.20% -54.45%
Operating Margin		 0.00% 0.00% -180.90% -179.91% -122.72% -574.85% -4,671.07% -72.84%
EBIT Margin		 0.00% 0.00% -180.90% -178.10% -122.72% -574.85% -4,671.07% -51.99%
Profit (Net Income) Margin		 0.00% 0.00% -176.55% -178.10% -115.17% -483.05% -3,921.10% -51.99%
Tax Burden Percent		 94.31% 94.81% 97.60% 100.00% 93.85% 84.03% 83.94% 100.00%
Interest Burden Percent		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -38.40% -44.22% -23.10% -19.91% -18.02% -23.28% -32.67% -10.92%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% 0.00% -17.19% -14.64% -16.25% -25.92% -36.88% -10.18%
Return on Assets (ROA)		 0.00% 0.00% -16.77% -14.64% -15.25% -21.78% -30.95% -10.18%
Return on Common Equity (ROCE)		 21.01% -11.98% -23.10% -19.91% -18.02% -23.28% -32.67% -10.92%
Return on Equity Simple (ROE_SIMPLE)		 70.17% -41.81% -17.40% -16.50% -16.78% -18.19% -25.91% 0.00%
Net Operating Profit after Tax (NOPAT)		 -25 -31 -25 -35 -44 -94 -229 -112
NOPAT Margin		 0.00% 0.00% -126.63% -125.94% -85.90% -402.40% -3,269.75% -50.99%
Net Nonoperating Expense Percent (NNEP)		 -9.84% -11.54% -5.08% -4.47% -4.02% -3.75% -5.32% -0.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - -12.52% -15.15% -21.61% -10.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 77.72% 71.76% 46.92% 121.04% 561.46% 28.95%
R&D to Revenue		 0.00% 0.00% 203.18% 208.15% 175.80% 553.81% 4,209.61% 143.89%
Operating Expenses to Revenue		 0.00% 0.00% 280.90% 279.91% 222.72% 674.85% 4,771.07% 172.84%
Earnings before Interest and Taxes (EBIT)		 -36 -44 -35 -50 -63 -134 -327 -114
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -36 -43 -33 -45 -60 -142 -346 -119
Valuation Ratios		 - - - - - - - -
Price to Book Value (P/BV)		 0.00 1.52 2.05 3.02 2.50 3.69 2.10 2.96
Price to Tangible Book Value (P/TBV)		 0.00 1.52 2.05 3.02 2.50 3.69 2.10 2.96
Price to Revenue (P/Rev)		 0.00 0.00 20.83 32.57 17.16 98.07 317.33 13.86
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 6.32 19.40 9.84 71.02 162.74 9.06
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 2.22 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 2.04 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.01 -1.00 -1.29 -1.30 -1.14 -1.04 -1.02 -1.02
Leverage Ratio		 1.08 1.10 1.38 1.36 1.18 1.07 1.06 1.07
Compound Leverage Factor		 1.08 1.10 1.38 1.36 1.18 1.07 1.06 1.07
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 154.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 -54.73% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 3.31 5.83 2.53 6.48 13.42 48.29 19.48 20.64
Noncontrolling Interest Sharing Ratio		 154.73% 72.90% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - -
Current Ratio		 16.75 14.65 7.47 5.56 11.68 19.65 14.97 11.34
Quick Ratio		 16.62 14.26 7.39 5.49 11.51 19.38 14.68 10.87
Cash Flow Metrics		 - - - - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -31 60 -54 -87 -106 -217 -108
Operating Cash Flow to CapEx		 -1,617.10% -2,905.62% 11,250.10% -2,109.64% -2,531.95% -4,865.88% -6,419.08% -3,002.45%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - -
Asset Turnover		 0.00 0.00 0.10 0.08 0.13 0.05 0.01 0.20
Accounts Receivable Turnover		 0.00 0.00 0.00 18.75 77.52 204.24 666.67 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 4.38 6.19 9.04 3.69 0.93 25.46
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 19.46 4.71 1.79 0.55 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 19.46 4.71 1.79 0.55 0.00
Capital & Investment Metrics		 - - - - - - - -
Invested Capital		 -0.52 -0.08 -85 -67 -24 -12 -23 -27
Invested Capital Turnover		 0.00 0.00 -0.46 -0.37 -1.13 -1.33 -0.41 -8.79
Increase / (Decrease) in Invested Capital		 0.00 0.44 -85 19 43 12 -11 -3.75
Enterprise Value (EV)		 98 52 123 542 501 1,661 1,139 1,981
Market Capitalization		 50 152 407 910 874 2,293 2,221 3,031
Book Value per Share		 ($51.19) $4.94 $6.82 $7.83 $7.26 $9.64 $12.25 $11.67
Tangible Book Value per Share		 ($51.19) $4.94 $6.82 $7.83 $7.26 $9.64 $12.25 $11.67
Total Capital		 89 100 198 302 349 621 1,059 1,023
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -90 -100 -284 -368 -373 -633 -1,082 -1,050
Capital Expenditures (CapEx)		 1.71 1.35 0.49 2.64 3.44 2.37 3.86 2.37
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -4.71 -4.24 -34 -41 -26 -20 -33 -31
Debt-free Net Working Capital (DFNWC)		 85 95 250 206 339 506 644 608
Net Working Capital (NWC)		 85 95 250 206 339 506 644 608
Net Nonoperating Expense (NNE)		 8.85 11 9.75 15 15 19 46 2.18
Net Nonoperating Obligations (NNO)		 -90 -100 -284 -368 -373 -633 -1,082 -1,050
Total Depreciation and Amortization (D&A)		 0.08 0.77 1.96 4.87 2.82 -7.55 -19 -5.38
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% -172.07% -146.50% -51.23% -83.74% -466.81% -14.39%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 1,279.38% 736.68% 665.09% 2,161.77% 9,194.89% 277.95%
Net Working Capital to Revenue		 0.00% 0.00% 1,279.38% 736.68% 665.09% 2,161.77% 9,194.89% 277.95%
Earnings Adjustments		 - - - - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 32.26M 38.63M 41.44M 57.52M 81.68M 88.49M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) ($1.42) ($1.96) ($3.36) ($1.28)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 32.26M 38.63M 41.44M 57.52M 81.68M 88.49M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 ($1.40) ($1.41) $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 24.72M 35.25M 48.39M 74.56M 87.54M 87.81M
Normalized Net Operating Profit after Tax (NOPAT)		 -25 -31 -25 -35 -44 -94 -229 -112
Normalized NOPAT Margin		 0.00% 0.00% -126.63% -125.94% -85.90% -402.40% -3,269.75% -50.99%
Pre Tax Income Margin		 0.00% 0.00% -180.90% -178.10% -122.72% -574.85% -4,671.07% -51.99%
Debt Service Ratios		 - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for IDEAYA Biosciences

This table displays calculated financial ratios and metrics derived from IDEAYA Biosciences' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 87,814,027.00 87,860,920.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 87,814,027.00 87,860,920.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -1.12 -1.28
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -2.46% -100.00% -100.00% -100.00% 78.43% 0.00% 0.00% 0.00% 55.37% 0.00% 0.00%
EBITDA Growth		 -67.99% -84.86% -105.66% -97.54% -231.52% -33.02% -28.09% 250.89% 36.06% -31.79% -35.37%
EBIT Growth		 -58.51% -67.39% -98.50% -99.53% -243.88% -41.48% -36.78% 262.13% 34.39% -36.52% -37.71%
NOPAT Growth		 -58.51% -94.14% -98.50% -99.53% -243.88% -65.41% -36.78% 331.61% 34.39% -28.62% -37.71%
Net Income Growth		 -40.30% -67.39% -88.97% -88.85% -283.78% -82.40% -46.84% 330.11% 36.10% -36.52% -45.12%
EPS Growth		 3.77% -8.16% -36.00% -30.43% -203.92% -54.72% -29.41% 321.67% 41.29% -35.37% -38.64%
Operating Cash Flow Growth		 -1.62% -57.36% 1.73% -63.17% -412.27% -37.73% -89.99% 388.85% 25.61% -24.57% -41.20%
Free Cash Flow Firm Growth		 32.35% 19.71% 52.29% 33.72% -115.36% 18.90% -55.25% 542.42% 30.15% -76.68% -44.72%
Invested Capital Growth		 51.39% 64.96% -148.36% -537.56% -99.76% -343.46% -52.89% -127.06% -16.29% -31.84% -36.53%
Revenue Q/Q Growth		 -51.19% -100.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% -94.77% -39.68% 35.02%
EBITDA Q/Q Growth		 -24.13% -0.08% -57.29% -1.10% -108.31% 49.58% -20.64% 219.09% -188.28% -3.91% -23.91%
EBIT Q/Q Growth		 -25.02% 5.59% -64.07% -3.03% -115.48% 49.92% -23.04% 222.12% -187.20% -4.20% -24.10%
NOPAT Q/Q Growth		 -25.02% -21.72% -27.27% -3.03% -115.48% 41.45% -5.23% 274.46% -161.04% -14.78% -12.66%
Net Income Q/Q Growth		 -23.74% -16.54% -33.36% 1.80% -151.47% 44.61% -7.36% 253.88% -169.83% -18.33% -14.12%
EPS Q/Q Growth		 -10.87% -3.92% -28.30% 11.76% -158.33% 47.10% -7.32% 251.14% -168.42% -21.98% -9.91%
Operating Cash Flow Q/Q Growth		 21.30% -84.49% 24.95% -49.73% -147.10% 50.40% -3.53% 327.64% -163.63% 16.94% -17.35%
Free Cash Flow Firm Q/Q Growth		 8.83% -13.25% 30.10% 8.15% -196.23% 57.35% -33.80% 361.73% -146.77% -7.88% -9.59%
Invested Capital Q/Q Growth		 -271.96% 47.06% -245.60% 6.32% -16.54% -17.54% -19.15% -39.12% 40.31% -33.25% -23.39%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,141.14% 0.00% 0.00% 0.00% -2,120.16% 0.00% 0.00% 51.72% -872.54% -1,503.16% -1,379.56%
Operating Margin		 -1,068.44% 0.00% 0.00% 0.00% -2,059.11% 0.00% 0.00% 52.18% -869.53% -1,654.63% -1,380.73%
EBIT Margin		 -1,068.44% 0.00% 0.00% 0.00% -2,059.11% 0.00% 0.00% 52.18% -869.53% -1,502.12% -1,380.73%
Profit (Net Income) Margin		 -865.54% 0.00% 0.00% 0.00% -1,861.60% 0.00% 0.00% 57.37% -765.66% -1,502.12% -1,269.64%
Tax Burden Percent		 76.21% 100.00% 81.28% 77.47% 83.76% 100.00% 87.26% 109.95% 136.14% 100.00% 91.95%
Interest Burden Percent		 106.30% 100.00% 100.00% 100.00% 107.94% 100.00% 100.00% 100.00% 64.68% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -23.28% -20.31% -21.45% -21.10% -32.67% -31.34% -35.09% -14.15% -10.92% -14.28% -16.22%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -48.17% 0.00% 0.00% 0.00% -16.26% 0.00% 0.00% 9.25% -170.30% -317.58% -275.01%
Return on Assets (ROA)		 -39.03% 0.00% 0.00% 0.00% -14.70% 0.00% 0.00% 10.17% -149.96% -317.58% -252.88%
Return on Common Equity (ROCE)		 -23.28% -20.31% -21.45% -21.10% -32.67% -31.34% -35.09% -14.15% -10.92% -14.28% -16.22%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -13.78% -16.50% -15.09% 0.00% -29.98% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -29 -36 -45 -47 -101 -59 -62 108 -66 -76 -86
NOPAT Margin		 -747.91% 0.00% 0.00% 0.00% -1,441.38% 0.00% 0.00% 52.18% -608.67% -1,158.24% -966.51%
Net Nonoperating Expense Percent (NNEP)		 -0.92% -0.60% -1.00% -0.58% -3.43% -1.32% -1.58% 0.92% -1.60% -2.23% -2.40%
Return On Investment Capital (ROIC_SIMPLE)		 -4.72% - - - -9.53% -5.77% -6.48% 9.93% -6.47% -8.11% -7.14%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 180.17% 0.00% 0.00% 0.00% 156.50% 0.00% 0.00% 7.89% 173.29% 295.40% 253.57%
R&D to Revenue		 988.27% 0.00% 0.00% 0.00% 2,002.61% 0.00% 0.00% 39.93% 796.24% 1,459.24% 1,227.15%
Operating Expenses to Revenue		 1,168.44% 0.00% 0.00% 0.00% 2,159.11% 0.00% 0.00% 47.82% 969.53% 1,754.63% 1,480.73%
Earnings before Interest and Taxes (EBIT)		 -42 -40 -65 -67 -144 -72 -89 108 -95 -99 -122
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -45 -45 -70 -71 -148 -75 -90 108 -95 -99 -122
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 3.69 3.02 2.85 2.27 2.10 1.40 1.92 2.18 2.96 3.12 2.73
Price to Tangible Book Value (P/TBV)		 3.69 3.02 2.85 2.27 2.10 1.40 1.92 2.18 2.96 3.12 2.73
Price to Revenue (P/Rev)		 98.07 182.42 222.17 682.23 317.33 204.84 263.00 11.10 13.86 12.99 13.99
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 71.02 121.71 142.52 376.30 162.74 54.67 121.30 5.81 9.06 8.67 8.68
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.04 -1.02 -1.02 -1.01 -1.02 -1.02 -1.03 -1.03 -1.02 -1.03 -1.04
Leverage Ratio		 1.07 1.05 1.05 1.05 1.06 1.05 1.07 1.07 1.07 1.09 1.09
Compound Leverage Factor		 1.14 1.05 1.05 1.05 1.14 1.05 1.07 1.07 0.69 1.09 1.09
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 48.76 64.90 37.95 27.14 20.02 10.87 12.95 15.83 20.69 18.36 17.31
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 19.65 28.42 17.50 22.93 14.97 13.92 12.39 12.44 11.34 10.74 10.45
Quick Ratio		 19.38 28.00 17.22 22.63 14.68 13.62 12.10 12.20 10.87 10.35 10.03
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -42 -47 -33 -30 -89 -38 -51 134 -62 -67 -74
Operating Cash Flow to CapEx		 -2,833.89% -3,306.64% -3,379.45% -10,773.30% -11,039.47% -4,536.99% -9,422.93% 338,604.76% -27,175.98% -7,773.53% -10,186.03%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.05 0.02 0.02 0.00 0.01 0.01 0.01 0.18 0.20 0.21 0.20
Accounts Receivable Turnover		 204.24 64.20 148.58 1.17 666.67 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 3.69 2.28 1.71 0.54 0.93 0.89 0.88 26.19 25.46 25.74 27.38
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 1.79 5.69 2.46 312.76 0.55 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 1.79 5.69 2.46 312.76 0.55 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -12 -6.10 -21 -20 -23 -27 -32 -45 -27 -36 -44
Invested Capital Turnover		 -1.33 -1.32 -0.81 -0.34 -0.41 -0.42 -0.26 -6.66 -8.79 -7.19 -6.15
Increase / (Decrease) in Invested Capital		 12 11 -13 -17 -11 -21 -11 -25 -3.75 -8.61 -12
Enterprise Value (EV)		 1,661 1,887 1,705 1,476 1,139 383 849 1,248 1,981 1,953 2,032
Market Capitalization		 2,293 2,828 2,657 2,676 2,221 1,434 1,841 2,385 3,031 2,926 3,275
Book Value per Share		 $9.64 $12.45 $12.31 $13.97 $12.25 $11.70 $10.96 $12.46 $11.67 $10.67 $13.65
Tangible Book Value per Share		 $9.64 $12.45 $12.31 $13.97 $12.25 $11.70 $10.96 $12.46 $11.67 $10.67 $13.65
Total Capital		 621 935 932 1,180 1,059 1,024 960 1,092 1,023 937 1,199
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -633 -941 -953 -1,200 -1,082 -1,051 -992 -1,137 -1,050 -973 -1,243
Capital Expenditures (CapEx)		 0.84 1.33 0.97 0.46 1.10 1.33 0.66 0.04 0.33 0.97 0.87
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -20 -14 -29 -28 -33 -35 -39 -49 -31 -40 -48
Debt-free Net Working Capital (DFNWC)		 506 684 672 892 644 657 630 738 608 631 781
Net Working Capital (NWC)		 506 684 672 892 644 657 630 738 608 631 781
Net Nonoperating Expense (NNE)		 4.61 3.86 7.32 5.00 29 13 15 -11 17 23 27
Net Nonoperating Obligations (NNO)		 -633 -941 -953 -1,200 -1,082 -1,051 -992 -1,137 -1,050 -973 -1,243
Total Depreciation and Amortization (D&A)		 -2.85 -5.23 -5.54 -4.35 -4.27 -2.65 -1.46 -0.95 -0.33 -0.07 0.10
Debt-free, Cash-free Net Working Capital to Revenue		 -83.74% -92.74% -244.30% -725.82% -466.81% -506.89% -563.91% -22.69% -14.39% -17.72% -20.33%
Debt-free Net Working Capital to Revenue		 2,161.77% 4,414.01% 5,621.91% 22,726.36% 9,194.89% 9,386.09% 9,003.77% 343.59% 277.95% 280.23% 333.73%
Net Working Capital to Revenue		 2,161.77% 4,414.01% 5,621.91% 22,726.36% 9,194.89% 9,386.09% 9,003.77% 343.59% 277.95% 280.23% 333.73%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.35 ($0.93) ($1.11) ($1.22)
Adjusted Weighted Average Basic Shares Outstanding		 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 88.53M 88.49M 88.70M 92.06M
Adjusted Diluted Earnings per Share		 ($0.51) ($0.53) ($0.68) ($0.60) ($1.55) ($0.82) ($0.88) $1.33 ($0.91) ($1.11) ($1.22)
Adjusted Weighted Average Diluted Shares Outstanding		 57.52M 75.11M 77.96M 86.19M 81.68M 88.36M 88.47M 89.69M 88.49M 88.70M 92.06M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 74.56M 75.69M 84.48M 86.43M 87.54M 87.58M 87.64M 87.67M 87.81M 87.86M 96.49M
Normalized Net Operating Profit after Tax (NOPAT)		 -29 -36 -45 -47 -101 -59 -62 76 -66 -76 -86
Normalized NOPAT Margin		 -747.91% 0.00% 0.00% 0.00% -1,441.38% 0.00% 0.00% 36.53% -608.67% -1,158.24% -966.51%
Pre Tax Income Margin		 -1,135.71% 0.00% 0.00% 0.00% -2,222.61% 0.00% 0.00% 52.18% -562.39% -1,502.12% -1,380.73%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

IDEAYA Biosciences’ Q2 2026 statements show a well-funded but still development-stage biotechnology company. Revenue was $8.9 million, up from $6.6 million in Q1 2026 but below the $207.8 million reported in Q3 2025. The sharp swings suggest that revenue is influenced by collaboration, licensing or milestone activity rather than a consistent commercial product base.

Profitability remains under pressure. IDEAYA reported a net loss of $112.5 million, compared with losses of $98.5 million in Q1 2026 and $83.3 million in Q4 2025. Research and development spending continues to rise, reaching $108.7 million in Q2 2026 versus $42.8 million in Q1 2024. Operating cash flow was negative $88.2 million in Q2, following negative cash flow of $75.2 million in Q1 and negative $90.5 million in Q4 2025.

The balance sheet is substantially stronger than it was several years ago. Cash and equivalents totaled $272.6 million, while short- and long-term investments totaled approximately $970.3 million. Total assets reached $1.31 billion, compared with $532.9 million in Q3 2023. However, much of the recent cash increase came from financing rather than operations: IDEAYA issued $358.4 million of common equity in Q2 2026, contributing to dilution.

  • Strong liquidity: Cash, short-term investments and long-term investments totaled approximately $1.24 billion at June 30, 2026, providing substantial funding for clinical development.
  • Low balance-sheet leverage: Total liabilities were only $110.8 million versus $1.20 billion of shareholders’ equity, limiting near-term debt and solvency risk.
  • Improved asset base: Total assets increased from $364.7 million in Q1 2023 to $1.31 billion in Q2 2026, supported by equity financings and accumulated investments.
  • Revenue remains present: Q2 2026 revenue of $8.9 million exceeded Q1 2026 revenue of $6.6 million, and the company has demonstrated an ability to generate materially larger collaboration-related revenue, including $207.8 million in Q3 2025.
  • Limited capital expenditures: Property and equipment purchases were only $866,000 in Q2 2026, indicating that the company’s cash needs are primarily tied to research and development rather than heavy infrastructure spending.
  • Large investment portfolio: IDEAYA held $556.4 million in short-term investments and $413.9 million in long-term investments. These assets may generate income and preserve flexibility, but their availability and value depend on investment terms and market conditions.
  • Investment activity drives cash movements: The company purchased $313.4 million of investments and sold or received maturities of $158.4 million in Q2 2026, making investing cash flow negative $155.9 million. This appears largely to reflect portfolio management rather than operating deterioration.
  • Persistent operating losses: IDEAYA has reported net losses in most recent quarters, including $112.5 million in Q2 2026. Retained earnings were negative $947.5 million at quarter-end.
  • Accelerating cash burn: Quarterly operating cash outflows increased from $32.9 million in Q2 2024 to $88.2 million in Q2 2026, reflecting the higher cost of advancing the pipeline.
  • Shareholder dilution: The Q2 2026 common equity issuance raised $358.4 million, while weighted-average basic shares rose to 92.1 million from 88.7 million in Q1 2026 and 57.5 million in Q4 2023. Future financing needs could create additional dilution.

Overall, IDEAYA’s financial position provides a meaningful cushion against its current cash burn, but the investment case remains dependent on clinical progress and future partnership or product revenue. Investors should weigh the substantial liquidity against rising research costs, recurring losses, volatile revenue and the company’s reliance on equity financing.

09/19/26 05:10 AM ETAI Generated. May Contain Errors.

IDEAYA Biosciences Financials - Frequently Asked Questions

According to the most recent income statement we have on file, IDEAYA Biosciences' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

IDEAYA Biosciences' net income appears to be on an upward trend, with a most recent value of -$113.70 million in 2025, rising from -$34.35 million in 2018. The previous period was -$274.48 million in 2024. Check out IDEAYA Biosciences' forecast to explore projected trends and price targets.

IDEAYA Biosciences' total operating income in 2025 was -$159.31 million, based on the following breakdown:
  • Total Gross Profit: $218.71 million
  • Total Operating Expenses: $378.02 million

Over the last 7 years, IDEAYA Biosciences' total revenue changed from $0.00 in 2018 to $218.71 million in 2025, a change of 21,871,000,000.0%.

IDEAYA Biosciences' total liabilities were at $86.39 million at the end of 2025, a 33.0% increase from 2024, and a 1,117.1% increase since 2018.

In the past 7 years, IDEAYA Biosciences' cash and equivalents has ranged from $20.51 million in 2018 to $157.02 million in 2023, and is currently $112.83 million as of their latest financial filing in 2025.

Over the last 7 years, IDEAYA Biosciences' book value per share changed from -51.19 in 2018 to 11.67 in 2025, a change of -122.8%.


Related Companies

Financial statements for NASDAQ:IDYA last updated on 8/4/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Here’s the stock symbol I’ve promised
Whitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...
Stansberry Research | Sponsoredtc pixel
These gold assets are priced for $1,800 gold [it's over $4,000]
Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...
Golden Portfolio | Sponsoredtc pixel
Your book is inside
The "Sucker's Bet" Most New Options Traders Fall For Most people who try options lose money the same way. ...
Profits Run | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on September 25. Altuche...
Paradigm Press | Sponsoredtc pixel
Here’s Why Trump Won’t End The Iran War
Trump has called an Iran deal close 38 times since the war began, yet the fighting keeps flaring back up. O...
Banyan Hill Publishing | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel